From Parabiosis to Plasma Exchange:
The Research
Twelve peer-reviewed studies that established therapeutic plasma exchange as a longevity intervention, summarized chronologically in plain language.
Over two decades, researchers have traced a direct line from animal experiments connecting young and old mice to FDA-cleared clinical procedures that measurably reduce biological age in humans. The key insight: aging is driven not by what the body lacks, but by what accumulates in blood plasma. Diluting those factors, through therapeutic plasma exchange, rejuvenates tissues, resets the immune system, and reverses molecular markers of aging across multiple organ systems.
Rejuvenation of aged progenitor cells by exposure to a young systemic environment
This foundational study demonstrated that exposing old mice to a young systemic environment through heterochronic parabiosis rejuvenated aged tissue stem cells. Key findings showed restored Notch signaling in aged muscle satellite cells, enhanced liver progenitor cell proliferation, and reversal of age-related molecular markers. Importantly, the effects were due to circulating factors, not cell migration (less than 0.1% of regenerated tissue came from the young partner), establishing that the systemic milieu modulates tissue regeneration.
At this time, the prevailing hypothesis was that beneficial molecules in the young animal’s plasma were responsible for rejuvenation, an interpretation that gave rise to "young blood" treatments and companies. What received less attention was the reciprocal finding: the young animals joined to old partners showed impaired tissue regeneration, suggesting old blood contained factors that were actively harmful. Later studies in this timeline would show that this second observation was the more important one.
The ageing systemic milieu negatively regulates neurogenesis and cognitive function
Villeda and colleagues showed that the aging systemic environment negatively regulates neurogenesis and cognitive function. Heterochronic parabiosis reduced neurogenesis in young mice exposed to old blood while increasing it in old mice exposed to young blood. They identified CCL11 (eotaxin) as a pro-aging chemokine elevated in aged plasma that inhibits neurogenesis, demonstrating that systemic factors drive brain aging.
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
This study confirmed that young blood reverses age-related cognitive impairments and improves synaptic plasticity in old mice. Young plasma infusions enhanced memory, learning, dendritic spine density, and long-term potentiation in the aged hippocampus, extending the established benefits of young blood beyond tissue regeneration to brain health.
These findings were initially interpreted as evidence that young plasma contains beneficial factors driving cognitive rejuvenation. However, later research (Papers 6 and 7) would demonstrate that the primary mechanism is likely dilution of pro-aging factors in old blood rather than addition of youthful components, reframing what these early plasma infusion studies were actually showing.
A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old blood
Rebo et al. developed a blood exchange system that isolated the effects of blood from the confounding variables of parabiosis (shared organs, hormones, environment). They demonstrated that old blood rapidly inhibits multiple tissues within days. A single exchange of old blood into young mice decreased muscle regeneration, hepatogenesis, and neurogenesis. Critically, old blood’s inhibitory effects were more pronounced than young blood’s benefits, particularly for neurogenesis, revealing that dilution of pro-aging factors may be more important than addition of youthful ones.
Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1
This study identified VCAM1 (vascular cell adhesion molecule-1) on brain endothelial cells as a key mediator of brain aging. When aged plasma was infused into young mice, it induced VCAM1 expression at the blood-brain barrier, demonstrating that circulating factors in old blood are directly harmful. VCAM1 activation triggered microglial reactivity and inhibited neural precursor cell activity. Anti-VCAM1 antibody treatment in aged mice reduced microglial activation, enhanced hippocampal neurogenesis, and improved cognitive performance, mimicking effects of young blood exposure. This study established VCAM1 as both a biomarker and therapeutic target, revealing how systemic aging factors communicate with the brain through the cerebrovascular interface.
This was another critical piece of evidence that the problem is what’s in old blood, not what’s missing from it. A specific molecule in aged plasma was shown to directly damage brain function, and blocking it was enough to restore cognitive performance without any young blood at all.
Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin
This study showed that young blood is not necessary for rejuvenation. Replacing 50% of old plasma with saline plus 5% albumin (a procedure the researchers called neutral blood exchange, and effectively the animal model of therapeutic plasma exchange) rejuvenated muscle, liver, and hippocampus in old mice. The effects matched or exceeded heterochronic parabiosis, demonstrating that dilution of pro-aging factors, rather than addition of young factors, drives multi-tissue rejuvenation. Critically, this was also the first study to analyze human plasma samples from TPE procedures, with proteomic analysis revealing a molecular resetting: pro-aging factors decreased while many pro-regenerative proteins actually increased, suggesting that accumulated pro-aging factors had been suppressing the body’s own repair mechanisms.
Plasma dilution improves cognition and attenuates neuroinflammation in old mice
This study expanded neutral blood exchange findings to cognitive function, showing that a single plasma dilution procedure rapidly improved memory and learning in old mice within one week. The procedure significantly reduced neuroinflammation: CD68+ activated microglia declined dramatically in the hippocampus, thalamus, and hypothalamus. Notably, plasma dilution was more effective than senolytic drugs (ABT 263) for brain rejuvenation, establishing it as a comprehensive intervention that targets multiple aging mechanisms simultaneously.
Attenuation of age-elevated blood factors by repositioning plasmapheresis: A novel perspective and approach
This review paper repositioned therapeutic plasma exchange (TPE), an FDA-cleared clinical procedure used for decades in autoimmune disease, as a potential rejuvenation therapy. It discussed how TPE attenuates age-elevated blood factors and proposed that diluting the systemic milieu, which accumulates pro-geronic factors with age, could be translated to clinical anti-aging interventions in humans. This paper bridged the gap between animal research and clinical application.
Systemic induction of senescence in young mice after single heterochronic blood exchange
Jeon et al. demonstrated that a single heterochronic blood exchange from old to young mice systemically induces cellular senescence throughout young tissues within days. Young animals rapidly acquired aging phenotypes: increased senescence markers, DNA damage, and inflammatory signals. Treating old donors with senolytic drugs before blood exchange prevented senescence induction in young recipients, revealing that circulating senescence-associated factors in old blood actively propagate aging.
Old plasma dilution reduces human biological age: A clinical study
The first clinical study demonstrating that TPE reduces human biological age. Repeated TPE treatments (5+ sessions) in older adults decreased biological age by 1–2 years as measured by epigenetic clocks and proteomic markers. The study defined “biological noise” (deregulation of key protein biomarkers — as a metric of aging). TPE restored youthful immune profiles, reduced cellular senescence and DNA damage markers, and normalized key signaling pathways (JAK-STAT, MAPK, TGF-beta, NF-κB), with TLR4 identified as a nodal point of molecular rejuvenation.
Multi-omics analysis of biological age rejuvenation following therapeutic plasma exchange
This comprehensive multi-omics clinical trial compared different TPE regimens across 30 participants. Biweekly TPE supplemented with IVIG produced the strongest biological age rejuvenation, decreasing biological age by 2.61 years after 3 sessions. The intervention reversed immune aging, reduced senescence-associated proteins, and improved multiple molecular profiles across epigenomics, proteomics, metabolomics, cytomics, and glycomics. Baseline health status predicted response magnitude, with individuals in poorer health showing the greatest benefit.
Impacts of systemic milieu on cerebrovascular and brain aging: Insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments
This extensive review synthesized two decades of research on how systemic factors influence cerebrovascular and brain aging. It comprehensively analyzed heterochronic parabiosis, blood exchange, and plasma transfer studies, documenting effects on neurogenesis, neuroinflammation, blood-brain barrier integrity, neurovascular coupling, and cognitive function. The review catalogued identified pro-geronic factors (including CCL11 and B2M) and anti-geronic factors (including GDF11, oxytocin, and TIMP2) and discussed translational strategies for modulating the systemic milieu to promote healthy brain aging.
What This Research Establishes
This body of work demonstrates that aging is substantially driven by the accumulation of pro-aging factors in blood plasma. The critical insight, validated across two decades of increasingly rigorous research, is that dilution of these factors through therapeutic plasma exchange, rather than addition of young factors, can rejuvenate multiple organ systems, reduce biological age, and improve healthspan.
TPE is an FDA-cleared procedure now supported by this growing body of peer-reviewed evidence for longevity applications. The research was conducted at institutions including UC Berkeley, Stanford University, the Buck Institute for Research on Aging, and Global Apheresis in Mill Valley, California, where Dr. Green practices today.
Have questions about the research behind TPE? Schedule a discovery call →